拉米夫定对HBV-DNA及HBeAg的影响研究

目的研究拉米夫定对乙型病毒性肝炎患者机体内HBV—DNA病毒含量及HBeAg的影响。方法选择我院87例拉米夫定治疗的乙肝患者为实验组，并以同期56例行一般护肝治疗的乙肝患者为对照组，研究两组不同治疗阶段HBV—DNA病毒载量及HBeAg的变化特点。结果两组治疗前HBV—DNA平均对数值经比较，差异无统计学意义（P〉0．05）；治疗3、6个月及1年两组HBV—DNA平均对数值比较，差异均有高度统计学意义（P〈0．01）；实验组HBV—DNA、HBeAg不同时期阳性率差异有高度统计学意义（P〈0．01），对照组HBV—DNA、HBeAg不同时期阳性率差异无统计学意义（P〉0．05）。结论拉米夫定对慢性乙型肝炎有很好的临床疗效。

Study of influence of Lamivudine on HBV-DNA and HBeAg

Objective To study the influence of Lamivudine on the HBV-DNA virus content and HBeAg in patients with viral B hepatitis.Methods A total of 87 patients with hepatitis B receiving Lamivudine treatment in our hospital were selected as the experiment group and 56 contemporary patients with hepatitis B receiving common live protection treatment were selected as the control group.The changes of HBV-DNA viral load and HBeAg in different treatment stages of the two groups were studied.Results The average log values of HBV-DNA before treatment between the two groups were not significantly different(P > 0.05);the average log values of HBV-DNA 3,6 months and 1 year after treatment were all significantly different between the two groups(P < 0.01).The positive rates of HBV-DNA and HBeAg in different stages of the experiment group were significantly different(P < 0.01);the positive rates of HBV-DNA and HBeAg in different stages of the control group were not significantly different(P > 0.05).Conclusion Lamivudine has good clinical curative effects in the treatment of chronic hepatitis B.